10.22376/ijpbs.2019.10.1.p1-12 Volume 6 Issue 1 2015 (January - March) Retrospective analysis of Oseltamivir and Zanamivir in 150 randomly-selected confirmed H lessThan sub greaterThan 1 lessThan /sub greaterThan N lessThan sub greaterThan 1 lessThan /sub greaterThan patients admitted into Medicine Department of Sassoon General Hospitals, Pune between 1 lessThan sup greaterThan st lessThan /sup greaterThan July 2009 and 31 lessThan sup greaterThan st lessThan /sup greaterThan December 2009 was undertaken.Patients predominantly in age group of 18-65 years received Oseltamivir alone or along with Zanamivir (57% males, 43% females). Mean hospital stay duration (days) was 5.2+1.97 in the combination group (n=81) as compared to 8.7+2.34 with Oseltamivir alone (n=69). Outcome was significantly better with the combination (85.18%) than Oseltamivir alone (62 %); in patients with high risk having associated comorbidities like Asthma, COPD, diabetes, CHD; in terms of treatment duration, survival and cure. The most common adverse effect with Oseltamivir therapy was gastrointestinal intolerance (48%) while bronchospasm was seen in 15 (18.51%) patients treated with Zanamivir.Oseltamivir-Zanamivir combination was superior to Oseltamivir monotherapy in patients of H lessThan sub greaterThan 1 lessThan /sub greaterThan N lessThan sub greaterThan 1 lessThan /sub greaterThan in the High-Risk Group. However, these findings need systematic prospective study for confirmation. HIMANSHU R. ARORA, KAVITA S SINGH AND B. B. GHONGANE H1N1, Neuraminidase inhibitors, Oseltamivir, Zanamivir, Drug toxicities 672-678